"Gonadotropin-Releasing Hormone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND.
- Gonadotropin-Releasing Hormone
- Gonadotropin Releasing Hormone
- LHFSH Releasing Hormone
- Releasing Hormone, LHFSH
- LH-Releasing Hormone
- LH Releasing Hormone
- LH-FSH Releasing Hormone
- LH FSH Releasing Hormone
- Luteinizing Hormone-Releasing Hormone
- Luteinizing Hormone Releasing Hormone
- FSH-Releasing Hormone
- FSH Releasing Hormone
Below are MeSH descriptors whose meaning is more general than "Gonadotropin-Releasing Hormone".
Below are MeSH descriptors whose meaning is more specific than "Gonadotropin-Releasing Hormone".
This graph shows the total number of publications written about "Gonadotropin-Releasing Hormone" by people in this website by year, and whether "Gonadotropin-Releasing Hormone" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Gonadotropin-Releasing Hormone" by people in Profiles.
An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Expert Opin Pharmacother. 2022 Mar; 23(4):421-429.
Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids. Expert Opin Drug Saf. 2022 Apr; 21(4):477-486.
Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids. J Womens Health (Larchmt). 2022 05; 31(5):698-705.
Accelerating functional gene discovery in osteoarthritis. Nat Commun. 2021 01 20; 12(1):467.
Assessment of children in the autistic spectrum disorder that carry the Thr92Ala-DIO2 polymorphism. J Endocrinol Invest. 2021 Aug; 44(8):1775-1782.
Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas. Obstet Gynecol. 2020 06; 135(6):1313-1326.
Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. Eur Urol. 2020 10; 78(4):603-614.
Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. N Engl J Med. 2020 01 23; 382(4):328-340.
Hormonal Contraceptives, Intrauterine Devices, Gonadotropin-releasing Hormone Analogues and Testosterone: Menstrual Suppression in Special Adolescent Populations. J Pediatr Adolesc Gynecol. 2019 Sep; 32(5S):S23-S29.
Development of an auxotrophic, live-attenuated Brucella suis vaccine strain capable of expressing multimeric GnRH. Vaccine. 2019 02 08; 37(7):910-914.